T1	Participants 812 990	systemic glucocorticoid treatment for graft-versus-host disease was given to 60 of the 92 participants (65%) in the BDP arm, versus 31 of 46 participants (67%) in the placebo arm
T2	Participants 1095 1125	The proportion of participants
